ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Texas » Hematology Oncology

Top Hematology Oncology Prescribers in Texas

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
JOHN HUNT M.D.

Hematology Oncology

20,191

$1.68M

507
265 are 65+

5%
patients receiving schedule two controlled substances

Avg: 8%

42%
patients receiving schedule three controlled substances

Avg: 17%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

30%
prescriptions for brand name drugs

Avg: 19%

$83
Average prescription price

Avg: $369

AMBROSE ABOUD MD

Hematology Oncology

10,047

$853K

409
292 are 65+

7%
patients receiving schedule two controlled substances

Avg: 8%

37%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

26%
prescriptions for brand name drugs

Avg: 19%

$85
Average prescription price

Avg: $369

TODD SHENKENBERG M.D.

Hematology Oncology

9,592

$1.57M

793
623 are 65+

7%
patients receiving schedule two controlled substances

Avg: 8%

21%
patients receiving schedule three controlled substances

Avg: 17%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$164
Average prescription price

Avg: $369

MELVIN HARRIS M.D.

Hematology Oncology

4,922

$289K

96
75 are 65+

0%
patients receiving schedule two controlled substances

Avg: 8%

42%
patients receiving schedule three controlled substances

Avg: 17%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$59
Average prescription price

Avg: $369

GERALD HAGIN M.D.

Hematology Oncology

4,551

$218K

416
359 are 65+

4%
patients receiving schedule two controlled substances

Avg: 8%

9%
patients receiving schedule three controlled substances

Avg: 17%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$48
Average prescription price

Avg: $369

ESTER POLLARD MD

Hematology Oncology

3,886

$542K

313
168 are 65+

18%
patients receiving schedule two controlled substances

Avg: 8%

42%
patients receiving schedule three controlled substances

Avg: 17%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$139
Average prescription price

Avg: $369

STEPHEN COHEN M.D.

Hematology Oncology

3,575

$1.34M

182
150 are 65+

14%
patients receiving schedule two controlled substances

Avg: 8%

30%
patients receiving schedule three controlled substances

Avg: 17%

4%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 19%

$374
Average prescription price

Avg: $369

ARIELLE LEE MD

Hematology Oncology

3,468

$745K

302
240 are 65+

6%
patients receiving schedule two controlled substances

Avg: 8%

17%
patients receiving schedule three controlled substances

Avg: 17%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$215
Average prescription price

Avg: $369

GARY GROSS MD

Hematology Oncology

3,312

$500K

285
219 are 65+

15%
patients receiving schedule two controlled substances

Avg: 8%

29%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$151
Average prescription price

Avg: $369

VICTORIA DORR MD

Hematology Oncology

2,907

$688K

291
175 are 65+

25%
patients receiving schedule two controlled substances

Avg: 8%

12%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

24%
prescriptions for brand name drugs

Avg: 19%

$237
Average prescription price

Avg: $369

ALEXANDER ZWEIBACH MD

Hematology Oncology

2,759

$961K

227
193 are 65+

9%
patients receiving schedule two controlled substances

Avg: 8%

14%
patients receiving schedule three controlled substances

Avg: 17%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 19%

$348
Average prescription price

Avg: $369

JAYASREE RAO M.D.

Hematology Oncology

2,720

$312K

351
277 are 65+

7%
patients receiving schedule two controlled substances

Avg: 8%

25%
patients receiving schedule three controlled substances

Avg: 17%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

9%
prescriptions for brand name drugs

Avg: 19%

$115
Average prescription price

Avg: $369

DAVID AUERBACH MD

Hematology Oncology

2,660

$160K

201
161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 8%

6%
patients receiving schedule three controlled substances

Avg: 17%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

25%
prescriptions for brand name drugs

Avg: 19%

$60
Average prescription price

Avg: $369

RAUL PORTILLO MD

Hematology Oncology

2,626

$964K

242
218 are 65+

8%
patients receiving schedule two controlled substances

Avg: 8%

10%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

23%
prescriptions for brand name drugs

Avg: 19%

$367
Average prescription price

Avg: $369

RUBEN SAEZ MD

Hematology Oncology

2,624

$775K

227
203 are 65+

5%
patients receiving schedule two controlled substances

Avg: 8%

14%
patients receiving schedule three controlled substances

Avg: 17%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

19%
prescriptions for brand name drugs

Avg: 19%

$295
Average prescription price

Avg: $369

PANAGIOTIS VALILIS M.D.

Hematology Oncology

2,533

$997K

313
242 are 65+

16%
patients receiving schedule two controlled substances

Avg: 8%

27%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$394
Average prescription price

Avg: $369

MICHAEL ASHIGBI M.D.

Hematology Oncology

2,455

$423K

218
174 are 65+

8%
patients receiving schedule two controlled substances

Avg: 8%

17%
patients receiving schedule three controlled substances

Avg: 17%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

18%
prescriptions for brand name drugs

Avg: 19%

$172
Average prescription price

Avg: $369

JIVESH SHARMA MD

Hematology Oncology

2,361

$1.18M

294
237 are 65+

14%
patients receiving schedule two controlled substances

Avg: 8%

19%
patients receiving schedule three controlled substances

Avg: 17%

6%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

20%
prescriptions for brand name drugs

Avg: 19%

$499
Average prescription price

Avg: $369

ROBERT DRODER M.D.

Hematology Oncology

2,162

$238K

256
198 are 65+

14%
patients receiving schedule two controlled substances

Avg: 8%

17%
patients receiving schedule three controlled substances

Avg: 17%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

15%
prescriptions for brand name drugs

Avg: 19%

$110
Average prescription price

Avg: $369

BALESH SHARMA MD

Hematology Oncology

2,138

$1.17M

402
336 are 65+

8%
patients receiving schedule two controlled substances

Avg: 8%

14%
patients receiving schedule three controlled substances

Avg: 17%

5%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 19%

$547
Average prescription price

Avg: $369

SYED RAZA M.D.

Hematology Oncology

2,077

$916K

369
324 are 65+

10%
patients receiving schedule two controlled substances

Avg: 8%

23%
patients receiving schedule three controlled substances

Avg: 17%

10%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

16%
prescriptions for brand name drugs

Avg: 19%

$441
Average prescription price

Avg: $369

MOHAMAD GHRAOWI MD

Hematology Oncology

2,044

$992K

276
208 are 65+

9%
patients receiving schedule two controlled substances

Avg: 8%

30%
patients receiving schedule three controlled substances

Avg: 17%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

21%
prescriptions for brand name drugs

Avg: 19%

$486
Average prescription price

Avg: $369

VICTOR HIRSCH MD

Hematology Oncology

2,028

$310K

227
169 are 65+

14%
patients receiving schedule two controlled substances

Avg: 8%

24%
patients receiving schedule three controlled substances

Avg: 17%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

17%
prescriptions for brand name drugs

Avg: 19%

$153
Average prescription price

Avg: $369

EDWARD EICHLER MD

Hematology Oncology

2,004

$541K

223
171 are 65+

10%
patients receiving schedule two controlled substances

Avg: 8%

27%
patients receiving schedule three controlled substances

Avg: 17%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

14%
prescriptions for brand name drugs

Avg: 19%

$270
Average prescription price

Avg: $369

STEVE PERKINS MD

Hematology Oncology

1,902

$908K

169
141 are 65+

12%
patients receiving schedule two controlled substances

Avg: 8%

28%
patients receiving schedule three controlled substances

Avg: 17%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 2%

22%
prescriptions for brand name drugs

Avg: 19%

$477
Average prescription price

Avg: $369

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank